Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

NCT06384820 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Decision

Conditions

Cutaneous Squamous Cell Carcinoma

Interventions

DRUG: cemiplimab
DRUG: fianlimab

Sponsor

Regeneron Pharmaceuticals